Trials / Completed
CompletedNCT00984581
Safety and Efficacy Study of Avotermin (Juvista) in Female Subjects
A Single-site, Double-blind Trial to Investigate the Safety, Tolerability, Systemic Exposure and Anti-scarring Potential of Intradermal Juvista in Female Subjects Aged 18-45 Years
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 35 (actual)
- Sponsor
- Renovo · Industry
- Sex
- Female
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
To assess safety and toleration, systemic exposure and anti-scarring potential of intradermal avotermin (Juvista) in young females.
Detailed description
Subjects were to receive two 1cm incisions on the upper, inner aspect of each arm (four wounds per subject). On Day 0 all subjects received intradermal Juvista at a concentration of 50ng/100ul to one incision site on Arm 1 and 5ng/100ul to one incision site on Arm 2. The other incision sites were injected with placebo. Following injection, 1cm incision wounds were made at each site. On Day 1 all subjects were re-injected with 100ul/cm intradermal Juvista or placebo to each side of the wound (200ul per incision) at the same concentration as for Day 0 (50 or 5ng/100ul). At month 6 all incision sites were excised for histological analysis and all excision sites injected with Juvista. Both sites on Arm 1 received 50ng/100ul/linear cm wound margin and both sites on Arm 2 received 5ng/100ul/linear cm wound margin. No excision sites received placebo. The appearance of excision scars was then assessed after 2, 4 and 6 months of healing i.e at months 8, 10 and 12 of the study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Avotermin | Intradermal injection, 5ng/100ul/linear cm wound margin administered on Day 0, Day 1 and month 6 |
| DRUG | Avotermin | Intradermal injection, 50ng/100ul/linear cm wound margin administered on Day 0, Day 1 and month 6 |
| DRUG | Placebo | Intradermal injection, 100ul/linear cm wound margin administered on Day 0 and Day 1 |
Timeline
- Start date
- 2003-04-01
- Primary completion
- 2004-08-01
- Completion
- 2004-08-01
- First posted
- 2009-09-25
- Last updated
- 2009-09-25
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT00984581. Inclusion in this directory is not an endorsement.